Status:
UNKNOWN
Lactoferrin in Covid-19 Hospitalized Patients
Lead Sponsor:
Paolo Manzoni
Conditions:
Covid19
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
TRIAL LAC is a randomized double-blind non profit multicenter study with a nutritional product: bovine lactoferrin - Mosiac 200 mg. the hypothesis to be confirmed is that bovine LF, administered dail...
Detailed Description
It has been shown with 'in vitro' studies that LF is able to prevent the entry of SARS-CoV-2 into the of the host cells. Overall, the available evidence suggests that LF may be a therapeutic option t...
Eligibility Criteria
Inclusion
- Hospitalization in non-ICU ward for Covid-19 infection, with virological diagnosis SARS-CoV2 confirmed via RT-PCR (or quick test)
- Age\>18 aa
- Covid symptomatology story from no more than 12 days
Exclusion
- Refusal of consent
- Need for immediate admission to intensive care
- Severe neoplasms (in advanced stage)
- Allergies or intolerances known to Lactoferrin
- 4\. Already being treated with Lactoferrin at the entrance to the Hospital 5. Patients with end-stage renal failure (stage 5) 6. Extremely serious general conditions to suggest an imminent exitus 7. Clinical conditions of absolute impossibility of tolerating ingestion of drugs/capsules due to conditions contraining the initiation of therapy for os.
Key Trial Info
Start Date :
January 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
194 Patients enrolled
Trial Details
Trial ID
NCT04847791
Start Date
January 14 2021
End Date
December 31 2022
Last Update
April 19 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
ASL BI Ospedale degli Infermi
Ponderano, Biella, Italy, 13875
2
AOU Ospedale Maggiore della Carità
Novara, Italy, 28100